Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.88 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.82 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.82 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.82 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.82 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.82 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.82 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.88 |
| ▸ | EYA2 | O00167 | 1/20 | 0.88 |
| ▸ | APP | P05067 | 1/20 | 0.88 |
| ▸ | BLM | P54132 | 2/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL291274 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL2789635 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL2522807 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8679211 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL15541077 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL23455628 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL21332394 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL20743376 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL21436997 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL4197393 | 1.00 | TDP1 (0.88) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091540-B2 | Grafted polymer bearing pendent cyclic carbonate functional groups | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2024-09-17 | — | — | US | disclosed |
| CN-116209772-A | Asparagine feed strategy for improving cell culture performance and reducing asparagine sequence variants | 瑞泽恩制药公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-3902791-B1 | NOVEL NITROGENOUS DIPOLE COMPOUNDS COMPRISING CYCLIC CARBONATE FUNCTIONS | MICHELIN & CIE (FR) | 2023-02-08 | — | — | EP | disclosed |
| CN-115097148-A | 25 hydroxy vitamin D detect reagent box | 山东博科生物产业有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220098400-A1 | GRAFTED POLYMER BEARING PENDENT CYCLIC CARBONATE FUNCTIONAL GROUPS | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2022-03-31 | — | — | US | disclosed |
| EP-3902791-A1 | NOVEL NITROGENOUS DIPOLE COMPOUNDS COMPRISING CYCLIC CARBONATE FUNCTIONS | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2021-11-03 | — | — | EP | disclosed |
| US-10952963-B2 | Ready to use liquid RECK formulation | QuVa Pharma, Inc. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3773479-A1 | READY TO USE LIQUID RECK FORMULATION | Quva Pharma, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020136332-A1 | RUBBER COMPOSITIONS BASED ON AT LEAST ONE COMPOUND BEARING CYCLIC CARBONATE FUNCTIONS | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020136330-A1 | NOVEL NITROGENOUS DIPOLE COMPOUNDS COMPRISING CYCLIC CARBONATE FUNCTIONS | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2020-07-02 | — | — | WO | disclosed |
| WO-1992010165-A1 | ENZYME CONTAINING DENTURE CLEANSER | WARNER-LAMBERT COMPANY (US) | 1992-06-25 | — | — | WO | disclosed |
| EP-0460720-A2 | A method of extruding liposomes | THE LIPOSOME COMPANY, INC. (US) | 1991-12-11 | — | — | EP | disclosed |
| US-5041278-A | Encapsulation; solvent-free; administration in vivo; antiinflammatory agents; analgesics; anesthetics | THE LIPOSOME COMPANY, INC. (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0414663-A4 | LIPOSOME CONTINUOUS SIZE REDUCTION METHOD AND APPARATUS | — | 1991-07-17 | — | — | EP | disclosed |
| EP-0414663-A1 | LIPOSOME CONTINUOUS SIZE REDUCTION METHOD AND APPARATUS | THE LIPOSOME COMPANY, INC. (US) | 1991-03-06 | — | — | EP | disclosed |
| US-4861580-A | Composition using salt form of organic acid derivative of alpha-tocopheral | THE LIPOSOME COMPANY, INC. (US) | 1989-08-29 | — | — | US | disclosed |
| WO-1988007850-A1 | LIPOSOME CONTINUOUS SIZE REDUCTION METHOD AND APPARATUS | THE LIPOSOME COMPANY, INC. (US) | 1988-10-20 | — | — | WO | disclosed |
| EP-0243446-A4 | ALPHA TOCOPHEROL-BASED VESICLES. | LIPOSOME CO INC (US) | 1988-06-23 | — | — | EP | disclosed |
| EP-0243446-A1 | ALPHA TOCOPHEROL-BASED VESICLES. | LIPOSOME CO INC (US) | 1987-11-04 | — | — | EP | disclosed |
| WO-1987002219-A1 | ALPHA TOCOPHEROL-BASED VESICLES | THE LIPOSOME COMPANY, INC. (US) | 1987-04-23 | — | — | WO | disclosed |